In this video, we delve into the fascinating world of big number multiplication and explore how computers perform this task ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

This week on STAT's podcast The Readout LOUD, hear about Biomarin's new chief business officer, Recursion's AI bona fides, and new findings on a GLP-1 and diabetes risk.

Recursion has stumbled through an early test of its tech-enabled drug discovery, reporting a hit on safety but failing to wow on the efficacy front.

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with ...

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...